Chief Strategy Officer at Syneos Health, Dr. Greg Licholai Joins NEMIC Board of Directors
Providence, Rhode Island | March 2026 — The New England Medical Innovation Center (NEMIC) is proud to announce the appointment of Dr. Greg Licholai to its Board of Directors. Dr. Greg Licholai is Chief Strategy Officer at Syneos Health. Previously he was Chief Medical & Innovation Officer at ICON plc where he has been President of Symphony Health and Care Innovations.
Dr. Licholai is currently on faculty of Yale School of Management, Co-Director of the Center for Digital Health and has been visiting faculty at Harvard Business School. Previously, he was President of rare disease at Moderna Therapeutics, President and Chief Medical Officer at Castle Creek Pharmaceuticals, and partner at McKinsey & Co. where he led the healthcare data business. He was also a senior executive at Proteostasis, Amicus Therapeutics and Medtronic Neurological as well as venture investor for Domain Associates and was co-founder of Immunome Therapeutics.
Dr. Licholai attended Harvard Business School, Yale School of Medicine, Columbia University and Boston College. He trained in Neurological Surgery at the Brigham and Women’s, Children’s, and Massachusetts General Hospitals. He serves on multiple company and non-profit boards including advisor to the Clinical Trials Transformation Initiative (CTTI), a public private partnership co-founded by Duke University and the Food and Drug Administration (FDA). Dr. Licholai writes about innovation in healthcare for Forbes, contributed to Digital Therapeutics Strategic, Scientific, Developmental, and Regulatory Aspects and his textbook Introduction to Medical Software: Foundations for Digital Health, Devices and Diagnostics is published by Cambridge University. He is on the board of the Epidermolysis Bullosa Research Partnership
“Dr. Licholai’s experience spans every stage of the healthcare innovation lifecycle—from bench science to venture investment to executive leadership,” said Dr. Jenny Hoffmann, Executive Director of NEMIC. “His insight and strategic vision will be instrumental as we continue building pathways for breakthrough technologies to reach patients.”
As NEMIC enters its next phase of growth, the addition of Dr. Licholai reflects the organization’s continued commitment to strengthening its governance with leaders who understand both the science and the business of healthcare innovation. His appointment reinforces NEMIC’s role as a hub for collaboration, commercialization, and company creation across New England.
We look forward to the insight, energy, and expertise he will bring to our community. Please join us in welcoming Dr. Greg Licholai to the NEMIC Board of Directors!
